Literature DB >> 1838060

Screening for microalbuminuria: which measurement?

S M Marshall1.   

Abstract

It now seems worth while to identify Type 1 diabetic patients with microalbuminuria, as improved blood glucose control and reduction of arterial blood pressure will slow if not prevent the progression to persistent proteinuria. Measurement of albumin excretion rate (AER) in a timed urine sample remains the gold standard for the definition of microalbuminuria, but is not a practical screening procedure. Thus attempts have been made to relate the albumin concentration of albumin:creatinine ratio in random or first morning urine samples to AER. There is a weak correlation of albumin concentration (r = 0.32 to 0.68) and albumin:creatinine ratio (r = 0.43 to 0.54) in a random urine sample with AER, and low sensitivity and specificity of a variety of different albumin concentrations and albumin:creatinine ratios to predict microalbuminuria. The correlation of albumin concentration (r = 0.86 to 0.90) and albumin:creatinine ratio (r = 0.74 to 0.91) in an early morning urine sample with AER is stronger. Measurement of albumin:creatinine ratio in an early morning urine sample appears to be the most reliable method of screening for microalbuminuria, with sensitivity of 88 to 100% and specificity 81 to 100% depending on the cut-off ratio chosen and the definition of microalbuminuria used. If the albumin:creatinine ratio in an early morning urine sample is less than or equal to 3.5 mg mmol-1, the patient can be classed as normoalbuminuric and re-screened annually. If the ratio is greater than or equal to 10.0 mg mmol-1, confirmation of microalbuminuria should be sought in a timed urine collection and appropriate therapy begun.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1838060     DOI: 10.1111/j.1464-5491.1991.tb01688.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  22 in total

1.  Microalbuminuria.

Authors:  P H Winocour
Journal:  BMJ       Date:  1992-05-09

2.  Chapter 1: Definition and classification of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

3.  Urinary albumin excretion and transcapillary escape rate of albumin in malignancies.

Authors:  L M Pedersen; L Terslev; P G SŁrensen; K H Stokholm
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

4.  Screening for diabetic microalbuminuria in routine clinical care: which method?

Authors:  J P Shield; L P Hunt; J D Baum; C A Pennock
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

5.  Microalbuminuria and nephropathy in insulin dependent diabetes mellitus.

Authors:  F M Campbell
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

6.  Urinary albumin excretion. Timed urine collections advisable.

Authors:  S M Marshall; J M MacLeod
Journal:  BMJ       Date:  1993-05-08

7.  Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus.

Authors:  C A Jones; G P Leese; S Kerr; K Bestwick; D I Isherwood; J P Vora; D A Hughes; C Smith
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

8.  Microalbuminuria in diabetes mellitus: Association with age, sex, weight, and creatinine clearance.

Authors:  N K Chowta; P Pant; M N Chowta
Journal:  Indian J Nephrol       Date:  2009-04

9.  Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010.

Authors:  Sharon H Saydah; Meda E Pavkov; Cindy Zhang; David A Lacher; Mark S Eberhardt; Nilka Rios Burrows; Andrew S Narva; Paul W Eggers; Desmond E Williams
Journal:  Clin Chem       Date:  2013-01-11       Impact factor: 8.327

10.  Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy.

Authors:  N Pasko; F Toti; A Strakosha; E Thengjilli; A Shehu; T Dedej; A Ylli; N Thereska
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.